Cargando…

Unmet Medical Needs and the Role of Pharmaceutical Companies

Rising health care costs have been prioritized in the budget planning of all Western countries. Rising R&D costs of up to $800 million per marketed new pharmaceutical have dramatically reduced the approval of new chemical entities (NCEs). Globalization of diseases like AIDS and SARS has had a de...

Descripción completa

Detalles Bibliográficos
Autor principal: Meyer-Sabellek, Wolfgang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121412/
http://dx.doi.org/10.1007/978-1-4020-8942-8_10
_version_ 1783515196586721280
author Meyer-Sabellek, Wolfgang
author_facet Meyer-Sabellek, Wolfgang
author_sort Meyer-Sabellek, Wolfgang
collection PubMed
description Rising health care costs have been prioritized in the budget planning of all Western countries. Rising R&D costs of up to $800 million per marketed new pharmaceutical have dramatically reduced the approval of new chemical entities (NCEs). Globalization of diseases like AIDS and SARS has had a definite impact on the economic situation not only in the Western world, but also in developing countries, especially for AIDS in Africa and SARS in Asia. The World Health Organization (WHO) is calling for free anti-tuberculosis (TB) drugs to be made available to people living with human immunodeficiency virus (HIV). The spread between unmet medical need in large indications (e.g. Alzheimer's disease) and in niche indications (e.g. Huntington disease) and the economic burden to create a blockbuster ($1 billion sales within one year after launch) has created a marketing-driven clinical development of new chemical entities. A paradigm shift has occurred by which developing a new innovative drug by documenting shortterm efficacy, quality and safety rather than long-term efficacy and emphasizing pharma-covilliglance including considerations of health economy within the medical environment a shift that has fundamentally changed and challenged the pharmaceutical industry.
format Online
Article
Text
id pubmed-7121412
institution National Center for Biotechnology Information
language English
publishDate 2009
record_format MEDLINE/PubMed
spelling pubmed-71214122020-04-06 Unmet Medical Needs and the Role of Pharmaceutical Companies Meyer-Sabellek, Wolfgang Quo Vadis Medical Healing Article Rising health care costs have been prioritized in the budget planning of all Western countries. Rising R&D costs of up to $800 million per marketed new pharmaceutical have dramatically reduced the approval of new chemical entities (NCEs). Globalization of diseases like AIDS and SARS has had a definite impact on the economic situation not only in the Western world, but also in developing countries, especially for AIDS in Africa and SARS in Asia. The World Health Organization (WHO) is calling for free anti-tuberculosis (TB) drugs to be made available to people living with human immunodeficiency virus (HIV). The spread between unmet medical need in large indications (e.g. Alzheimer's disease) and in niche indications (e.g. Huntington disease) and the economic burden to create a blockbuster ($1 billion sales within one year after launch) has created a marketing-driven clinical development of new chemical entities. A paradigm shift has occurred by which developing a new innovative drug by documenting shortterm efficacy, quality and safety rather than long-term efficacy and emphasizing pharma-covilliglance including considerations of health economy within the medical environment a shift that has fundamentally changed and challenged the pharmaceutical industry. 2009 /pmc/articles/PMC7121412/ http://dx.doi.org/10.1007/978-1-4020-8942-8_10 Text en © Springer-Verlag Berlin Heidelberg 2009 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Article
Meyer-Sabellek, Wolfgang
Unmet Medical Needs and the Role of Pharmaceutical Companies
title Unmet Medical Needs and the Role of Pharmaceutical Companies
title_full Unmet Medical Needs and the Role of Pharmaceutical Companies
title_fullStr Unmet Medical Needs and the Role of Pharmaceutical Companies
title_full_unstemmed Unmet Medical Needs and the Role of Pharmaceutical Companies
title_short Unmet Medical Needs and the Role of Pharmaceutical Companies
title_sort unmet medical needs and the role of pharmaceutical companies
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7121412/
http://dx.doi.org/10.1007/978-1-4020-8942-8_10
work_keys_str_mv AT meyersabellekwolfgang unmetmedicalneedsandtheroleofpharmaceuticalcompanies